Global Medical REIT Inc. (GMRE)
Valuation Overview•Is Global Medical REIT Inc. Overvalued or Undervalued?
Trading at a relative discount to industry peers, suggesting a specific risk premium is applied.
Fragile underlying quality score of 41/100; weak margins or elevated debt leverage warrant caution.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Average quality business weighed down by significant profitability concerns.
Wall Street is broadly bullish, projecting solid upside alongside robust expected earnings growth. This outlook is strongly supported by highly attractive capital returns, anchored by a strong, well-covered dividend yield.
GMRE struggles with subpar profitability and pressured margins. This is backed by a fortress balance sheet, holding significant net cash ($9M) and minimal debt risk.
The company exhibits steady, low-single-digit revenue growth paired with stable bottom-line earnings. The company maintains healthy operational efficiency with a 20.5% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $35.2M | +7.1% | +2.6% | +9.6% | +53.3% | |
| EBITDA | $16.5M | — | -6.9% | — | — | |
| Net Income | -$11.8M | -282.7% | — | — | -22.4% | |
| EPS (Diluted) | $-0.55 | -393.5% | — | — | +40.4% | |
| Free Cash Flow | -$88.0M | +393.6% | — | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 49.9% | 79.5% | 81.8% | 86.2% |
| Operating Margin | 20.5% | 25.2% | 27.7% | 27.5% |
| Net Margin | -8.2% | 3.7% | 8.1% | -0.2% |
| FCF Margin | -24.3% | 24.3% | -19.9% | -359.4% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q4'25Latest | $1.05 | $1.12 | +6.7% | ||
| Q3'25 | $1.15 | $1.15 | +0.0% | ||
| Q2'25 | $0.22 | $0.22 | +0.0% | ||
| Q1'25 | $0.01 | $0.22 | +2100.0% | ||
| Q4'24 | $0.23 | $0.22 | -4.3% | ||
| Q3'24 | $0.22 | $0.22 | +0.0% | ||
| Q2'24 | $0.24 | $0.23 | -4.2% | ||
| Q1'24 | $0.24 | $0.23 | -4.2% |
Total return is +22.0% (1Y), lagging the benchmark by -3.0%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +7.7% | -1.6% | — |
| 1Y | +22.0% | -3.0% | +9.4% |
| 3YCAGR | -0.2% | -19.7% | +24.1% |
| 5YCAGR | -5.7% | -18.8% | +26.6% |
| 10YCAGR | +15.1% | +1.5% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Global Medical REIT Inc. (GMRE) valuation, health, and returns.
Based on peer relative multiples, Global Medical REIT Inc. appears Cheap versus peers compared to industry peers.
Global Medical REIT Inc. has multiple valuation anchors: Peer Relative Fair Value: $57.70 | Wall Street Analyst Target: $40.00 (implying +11.9% upside). A convergence of these signals offers higher conviction.
Global Medical REIT Inc. displays fair financial health with a composite quality score of 41/100, supported by a Piotroski F-Score of 3/9.
Global Medical REIT Inc. pays a 63.5% dividend yield, covered by a 0% payout ratio with 0 years of growth, supplemented by a 0.0% buyback yield.
Global Medical REIT Inc.'s current growth trajectory is Accelerating. The company achieved +7.1% 1Y revenue growth and -393.5% 1Y EPS growth, compared to its 3Y revenue CAGR of +2.6%.
Wall Street consensus is Buy based on 22 analysts, beating EPS expectations in 25% of recent quarters with a 1-quarter streak. The consensus price target represents a +11.9% change from current levels.
Investment risks for Global Medical REIT Inc. include: -22.0% 1-year max drawdown. Volatility risk is characterized by a beta of 0.40x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.